Please assess the completion status of the following clinical trial:

Trial Title: Phase2a Primaquine Dose Escalation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age \>= 18 years and \< 50 years~* Malaria blood thick film positive~* Presence of gametocytes on thick blood film~* Agrees to admission to study ward for 26 hours post diagnosis and available for follow up visits~* No allergies to study drugs~* Hemoglobin \>= 8 g/dl~* No evidence of severe or chronic disease~* Written, informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- dihydroartemisinin-piperaquine only (Type: ACTIVE_COMPARATOR): dihydroartemisinin -piperaquine (DP) only
- DP and 0.125 mg/kg primaquine (Type: EXPERIMENTAL): DP and single dose oral 0.125 mg/kg primaquine
- DP and 0.5 mg/kg primaquine (Type: EXPERIMENTAL): DP and single dose oral 0.5 mg/kg primaquine
- DP and 0.25 mg/kg primaquine (Type: EXPERIMENTAL): DP and a single dose oral 0.25 mg/kg primaquine
- DP and 0.0625 mg/kg primaquine (Type: EXPERIMENTAL): DP and a single dose oral 0.0625 mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).